Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | CNR1 | P21554 | 4/20 | 0.43 |
| ▸ | CCNA2 | P20248 | 2/20 | 0.40 |
| ▸ | CDK2 | P24941 | 2/20 | 0.40 |
| ▸ | CCNA1 | P78396 | 2/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | MAP2K4 | P45985 | 1/20 | 0.38 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.38 |
| ▸ | MAPKAPK3 | Q16644 | 1/20 | 0.38 |
| ▸ | MAPK6 | Q16659 | 1/20 | 0.38 |
| ▸ | BACE1 | P56817 | 1/20 | 0.38 |
| ▸ | NQO2 | P16083 | 1/20 | 0.38 |
| ▸ | DHODH | Q02127 | 1/20 | 0.37 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.37 |
| ▸ | KDR | P35968 | 1/20 | 0.37 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.37 |
| ▸ | CCNE2 | O96020 | 1/20 | 0.37 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9998065 | 0.79 | CNR1 (0.46) | KDM4ECNR1CCNA2CDK2CCNA1 | |
| SCHEMBL14477435 | 0.79 | KDM4E (0.41) | KDM4ECNR1CCNA2CDK2CCNA1 | |
| SCHEMBL12032468 | 0.77 | CCNA2 (0.41) | KDM4ECNR1CCNA2CDK2CCNA1 | |
| SCHEMBL2719952 | 0.77 | KDM4E (0.44) | KDM4ECCNA2CDK2CCNA1MAPK1 | |
| SCHEMBL4421437 | 0.74 | RIPK2 (0.53) | KDM4ECDK2MAPK1MAP2K4MAPKAPK2 | |
| SCHEMBL12861090 | 0.73 | SRC (0.32) | — | |
| SCHEMBL12034330 | 0.73 | TRPA1 (0.45) | KDM4ECCNA2CDK2CCNA1NQO2 | |
| SCHEMBL9998167 | 0.73 | ERN1 (0.37) | — | |
| SCHEMBL29665255 | 0.73 | ALOX15 (0.39) | — | |
| SCHEMBL6112367 | 0.73 | MAPT (0.41) | CNR1CCNA2CDK2CCNA1MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-103097375-B | Cyclohexyl-azetidine the antagonist of CCR2 | JANSSEN PHARMACEUTICA N.V. (BE) | 2015-08-12 | — | — | CN | disclosed |
| EP-2582692-B1 | CYCLOHEXYL-AZETIDINYL ANTAGONISTS OF CCR2 | JANSSEN PHARMACEUTICA NV (BE) | 2015-07-22 | — | — | EP | disclosed |
| EP-2582692-B1 | CYCLOHEXYL-AZETIDINYL ANTAGONISTS OF CCR2 | JANSSEN PHARMACEUTICA NV (BE) | 2015-07-22 | — | — | EP | disclosed |
| US-9062048-B2 | Cyclohexyl-azetidinyl antagonists of CCR2 | JANSSEN PHARMACEUTICA NV (BE) | 2015-06-23 | — | — | US | disclosed |
| US-9062048-B2 | Cyclohexyl-azetidinyl antagonists of CCR2 | JANSSEN PHARMACEUTICA NV (BE) | 2015-06-23 | — | — | US | disclosed |
| US-20130310365-A1 | CYCLOHEXYL-AZETIDINYL ANTAGONISTS OF CCR2 | JANSSEN PHARMACEUTICAL NV (BE) | 2013-11-21 | — | — | US | disclosed |
| US-8518969-B2 | Cyclohexyl-azetidinyl antagonists of CCR2 | JANSSEN PHARMACEUTICA NV (BE) | 2013-08-27 | — | — | US | disclosed |
| US-8518969-B2 | Cyclohexyl-azetidinyl antagonists of CCR2 | JANSSEN PHARMACEUTICA NV (BE) | 2013-08-27 | — | — | US | disclosed |
| CN-103097375-A | Cyclohexyl-azetidinyl antagonists of CCR2 | JANSSEN PHARMACEUTICA NV | 2013-05-08 | — | — | CN | disclosed |
| EP-2582692-A1 | CYCLOHEXYL-AZETIDINYL ANTAGONISTS OF CCR2 | Janssen Pharmaceutica, N.V. (BE) | 2013-04-24 | — | — | EP | disclosed |
| US-20110312936-A1 | CYCLOHEXYL-AZETIDINYL ANTAGONISTS OF CCR2 | JANSSEN PHARMACEUTAICA N.V. (BE) | 2011-12-22 | — | — | US | disclosed |
| US-20110312936-A1 | CYCLOHEXYL-AZETIDINYL ANTAGONISTS OF CCR2 | JANSSEN PHARMACEUTAICA N.V. (BE) | 2011-12-22 | — | — | US | disclosed |
| WO-2011159854-A1 | CYCLOHEXYL-AZETIDINYL ANTAGONISTS OF CCR2 | JANSSEN PHARMACEUTICA NV (BE) | 2011-12-22 | — | — | WO | disclosed |
| WO-2011159854-A1 | CYCLOHEXYL-AZETIDINYL ANTAGONISTS OF CCR2 | JANSSEN PHARMACEUTICA NV (BE) | 2011-12-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110312936-A1 | CYCLOHEXYL-AZETIDINYL ANTAGONISTS OF CCR2 | CCR2, CCR1, CCR5 | KDM4E 822/4885CNR1 41/4885CCNA2 566/4885 |
| US-20130310365-A1 | CYCLOHEXYL-AZETIDINYL ANTAGONISTS OF CCR2 | CCR2, CCR1, CCR5 | KDM4E 822/4885CNR1 41/4885CCNA2 566/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.